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OBJECTIVES: Exposure to topical bovine-derived thrombin has been associated with 
post-operative immune-mediated coagulopathy (IMC). Although rare, IMC has been 
associated with poor outcomes and additional clinical and ﬁnancial burden. Formal 
economic analyses of IMC events have not been performed, in part due to the lack of 
speciﬁc diagnostic codes. The goal of this descriptive study was to develop a novel 
approach to estimate the economic burden and resource utilization in patients where 
the presence of this adverse event was suspected. METHODS: Data for bovine throm-
bin-exposed patients discharged between January 2005 and March 2009 were 
extracted from Premier’s PerspectiveTM database. Coagulopathies were identiﬁed utiliz-
ing a clinical algorithm based on laboratory tests and/or consultations consistent with 
investigation of suspected coagulopathies, including IMC. The index hospitalization 
was the ﬁrst observed use of bovine thrombin and suspected IMC in the study period. 
Length of stay (LOS), ICU LOS, total, and departmental costs per patient were cal-
culated for the index hospitalization and any subsequent hospitalization with sus-
pected coagulopathy. Costs were adjusted to 2009 dollars. RESULTS: A total of 450 
patients exposed to bovine thrombin met the deﬁned criteria for a suspected coagu-
lopathy during their index hospitalization. Five of these patients had suspected coagu-
lopathy during a subsequent hospitalization. The estimated total cost [median (range)] 
associated with the index and subsequent hospitalizations was $62,373 ($1,385-
$1,368,706), including costs in pharmacy $7,404 ($237-$990,267), laboratory $6,098 
($247-$250,718), and blood bank $3,019 ($15-$264,943). Total hospital LOS 
[median (range)] was 21 days (1–1,027), with a median ICU LOS of 13 days (2–161). 
CONCLUSIONS: The approach used in this study may be useful in quantifying the 
medical resources utilized by patients developing IMC after exposure to bovine throm-
bin. Further evaluation of the cost of IMC is warranted because these iatrogenic events 
may be preventable.
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OBJECTIVES: The number of surgical procedures that require anesthesia and the 
costs associated with them continues rising, in many cases inﬂuenced by the use of 
newer and more expensive anesthetics. Our aim was to develop a tool to assess the 
costs and resource use in anesthesia in Colombia. METHODS: An excel tool to cal-
culate the resource use and costs of medications used for anesthesia was developed. 
Costs were derived from the hospital pharmacy in a third level institution in Bogota, 
Colombia, and validated with other reliable sources. The model is capable of simulat-
ing the resource use and costs associated with speciﬁc procedures. It uses the subject’s 
age, sex, weight and height as variables to determine the dosages of the different drugs, 
as well as the time estimated for the procedure to determine resource utilization. 
Finally, the costs are calculated based on the previous variables and the speciﬁc anes-
thetic technique selected, identifying the different combinations of drugs, equipment, 
and adding a waste factor for the inhalation anesthetics. RESULTS: The 2 most 
common surgical procedures performed under general anesthesia in the institution, 
laparoscopic cholecystectomy and laparoscopic hysterectomy, were selected for the 
simulation using 3 common forms of anesthesia: balanced analgesic-based, balanced 
hypnotic-based. Each one of these forms of anesthesia uses a different set of drugs 
and dosages, and they could be used interchangeably according to the anesthesiologist 
preference in most cases. The results of the simulations showed that the resource use 
and the total cost of the anesthesia provided varied across these three forms, depending 
mainly on the length of the procedure and the patient’s characteristics. CONCLU-
SIONS: The use of tools to determine resource use and costs in procedures that require 
anesthesia may help physicians and decision makers to compare interchangeable forms 
of anesthesia to optimize their resources.
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OBJECTIVES: Fibrin sealants (FS) are used during surgical procedures to achieve 
hemostasis, as sealants and to adhere tissues or implants to tissue. Because of added 
costs FS are not used in every procedure that could beneﬁt. This study compared the 
average costs of incisional hernia procedures with and without use of FS. METHODS: 
Spanish cost data were applied to results from a prospective, randomized controlled 
trial of sixty patients undergoing incisional hernia with dermolipectomy treated with 
FS (TISSEEL, Baxter Healthcare) or no FS (controls). Data obtained from the clinical 
study included: Use of FS, prophylactic antibiotics and antithrombotics, duration of 
hospital stay, postoperative morbidity, need for blood transfusions and hernia recur-
rence. The study compared the average cost per surgery in both groups, the incremen-
tal cost for FS and the average costs for treatment of adverse events (AE) attributed 
to the surgery. RESULTS: Based on reported resource use the average costs per inci-
sional hernia case were calculated as 37,284 and 312,744 for surgeries with and 
without FS use, respectively. The major cost driver was differences in hospitalization 
length between the treatment arms. A sensitivity analysis that excluded hospitalization 
costs still found FS to be cost-saving. Signiﬁcant differences in hematoma rates and 
blood transfusions increased the average costs per surgery by 31.77 and 343.20 in the 
control group, respectively. The cost of FS represented 2.5% of total costs in active 
treatment arm (3179 per surgery). These results are only applicable to Spain and 
countries with similar clinical outcomes and costs structures. Though, this model can 
easily be adapted as long as only the cost structure differs. CONCLUSIONS: The 
results suggest the costs of FS in incisional hernia may be offset by reduced ancillary 
surgical costs and shorter hospitalization periods. Future prospective randomized 
studies collecting more detailed resource use data are necessary to validate these 
ﬁndings.
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OBJECTIVES: We conducted a literature review on the adverse drug reaction(ADR) 
of 33 variety of traditional Chinese medicine injections(TCMIs) on the national 
essential medicine list (2004 edition). METHODS: We electronically searched three 
major Chinese Databases(CBM, CNKI, VIP) since their inception to end-April, 2009. 
We also retrieved the websites of Ministry of Health and State Food and Drug Admin-
istration as well as Newsletter of Adverse Drug Reactions (issue 1 to 22). We descrip-
tively analyzed the TCMIs ADR literatures. RESULTS: Among 5405 citations 
searched, only 1010 studies met the eligible criteria. The total and cumulative amounts 
of included articles about TCMIs ADRs signiﬁcantly increase over time. The included 
1010 articles were scattered among 297 periodicals, including 55 journals on phar-
maceutical medicine (containing 399 articles, accounted for 39.50%) and 64 journals 
on traditional Chinese medicine(containing only 197 articles, amounted for 19.50%). 
The articles included were categorized into eight types of design as follows: 348 case 
reports and 254 case series which accounted for 34.46% and 25.15% of the total 
articles, 119 overviews (11.78%), 116 randomized control trials (11.49%), 78 cross-
sectional studies (7.72%), 61 ADR literature analyses (6.04%), and 28 non-random-
ized controlled clinical studies (2.77%). The reports of ADRs to Shuanghuanglian, 
Qingkailing and Yuxingcao injections were the most in all reports for TCMIs (more 
than 200 articles for each injections, accounting for 41.95% of the total). The four 
kinds of TCMIs (Shuanghuanglian, Ciwujia, Yuxingcao, Yinzhihuang injections) 
among the top 5 reported ADR literatures were removed for the market. CONCLU-
SIONS: Articles published on TCMIs ADRs increased year by year, but the research 
is of low quality and is scattered in a large number of sources. Four TCMIs (Shuan-
ghuanglian, Ciwujia, Yuxingcao, and Yinzhihuang) among the top 5 ADR literatures 
reported were terminated for sale and use. It is necessary to enforce safety re-evalua-
tion of TCMIs and to promote the clinical rational use.
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OBJECTIVES: Attention-deﬁcit/hyperactivity disorder (ADHD) is a common mental 
illness of childhood, and the methylphenidate (MPH) is the most use and effective 
drugs in treating ADHD. Some recent studies found long-term use of MPH could 
cause side effects (SE) such as cardiovascular disease, mental illness, and substance 
abuse. This study focused on the pharmacological treatment of ADHD using MPH, 
and to evaluate the relationship between MPH and potential SE speciﬁcally on above 
three diseases. METHODS: The data source was the overall ADHD patients’ cohort 
during 2000∼2007 from a population-based dataset, the National Health Insurance 
Research Database, in Taiwan. Children (aged 6–18) having newly diagnosed ADHD 
was included from claims data between January 1, 2001 and December 31, 2006. 
Newly diagnosed patient was identiﬁed as no diagnosed record before 12 months since 
initial ADHD diagnosed and data on SE were collected during the 12 months after 
each patient’s initial ADHD diagnosed. These patients were divided into two groups 
according to whether they were using MPH or not. RESULTS: We captured 61,878 
new diagnosed cases (27,656 cases in MPH group, 34,222 in non-MPH group) during 
the study period. The Cox proportional hazards model analysis demonstrated that the 
MPH group have no signiﬁcant higher hazard ratio (HR) of diagnose for cardiovas-
cular disease and substance abuse. However, the MPH group have signiﬁcant higher 
HR of diagnose for mental illness such as oppositional deﬁant disorder (HR = 1.737, 
95% CL: 1.333–2.264) and anxiety disorders (HR = 2.858, 95% CL: 2.517–3.244). 
CONCLUSIONS: Taking methylphenidate to treat ADHD did not increase HR of 
cardiovascular disease and substance abuse, but may have potential side effect of some 
mental illness such as oppositional deﬁant disorder and anxiety disorders.
